Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin

BACKGROUND AND PURPOSE: Polatuzumab vedotin is an antibody–drug conjugate (ADC) being developed for non‐Hodgkin's lymphoma. It contains a humanized anti‐CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), an anti‐mitotic agent. Polatuzumab vedotin binds to human CD79b only....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dongwei, Lee, Donna, Dere, Randall C., Zheng, Bing, Yu, Shang‐Fan, Fuh, Franklin K., Kozak, Katherine R., Chung, Shan, Bumbaca Yadav, Daniela, Nazzal, Denise, Danilenko, Dimitry, Go, Mary Ann T., Williams, Marna, Polson, Andrew G., Poon, Kirsten Achilles, Prabhu, Saileta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780994/
https://www.ncbi.nlm.nih.gov/pubmed/31270798
http://dx.doi.org/10.1111/bph.14784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780994/
https://www.ncbi.nlm.nih.gov/pubmed/31270798
http://dx.doi.org/10.1111/bph.14784

Ejemplares similares